The Factor That Makes or Breaks Renewals, Expansions, and Long-Term U.S. Adoption The first sale gets all the attention. It's the LinkedIn post. The celebratory email. The board slide with another hospital logo added to the pipeline because apparently one contract means world domination now. Unfortunately, it's also the sale that's most likely losing you money. Step 8 was about getting a hospital live. Step 9 is about making sure they never want to leave. Launch is an event.

FDA clearance is not the same thing as commercial readiness. In Step 1 of the MedTech Recovery Program, we break down why clinical data, KOL strategy, study design, and early site selection often fail to translate into real U.S. adoption. Learn how successful MedTech companies build commercially relevant evidence before entering hospital systems, Value Analysis Committees, and skeptical physician workflows.

FDA clearance is not a commercial strategy. It's permission to start building one. That distinction matters more than most international MedTech founders realize until they've already arrived in the U.S. market, pitch deck in hand, expecting momentum. What they find instead: Clinical skepticism Procurement committees Reimbursement walls Hospital IT And Decision-makers with zero emotional investment in their technology. Clearance doesn't protect you from any of that. Over the